Screening and Treatment Using a Risk-Based Approach With NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study.
https://t.co/Zw6CR1A3ZD
Contributions from Baim faculty, @ambarish4786 and @JavedButler1.
#BaimInstitute#ClinicalResearch#DM
Defining Clinically Meaningful Within-Patient Changes in Heart Failure: JACC: Heart Failure Position Statement.
https://t.co/T07D5aX1vn
Contributions from Baim CSO, James Januzzi, and Baim faculty, @JavedButler1.
#BaimInstitute#ClinicalResearch#HeartFailure
Prof. Javed Butler makes the case for upstream #NLRP3 inhibition: targeting inflammasome activation closer to plaque-level danger signalling may matter for residual inflammatory risk.
Watch the video here: https://t.co/oAehPHSzdt
Optimal implementation of SGLT2i to the 57.5 million US adults with T2DM, HF or CKD:
🫀 ~362,000 fewer HF 🏨/year
✅ ~224,000 deaths prevented/year
💰 $24.9 billion net savings/year
📈 ~$10 back per $1 spent (generic pricing)
#SGLT2i more than pays for itself
Albuminuria and heart failure
UACR AND HEART FAILURE: A CARDIORENAL WARNING SIGNAL
Albuminuria is more than a marker of kidney damage. It is an independent predictor of incident and worsening heart failure, hospitalization and mortality.
📊 Key messages:
🔹 HF risk rises progressively with increasing UACR—even at low levels of albuminuria.
🔹 Across multiple studies, albuminuria is associated with approximately 1.5- to 6-fold higher HF risk, depending on the population and UACR level.
🔹 Its prognostic value extends beyond kidney disease, including in patients with diabetes and atrial fibrillation.
🔹 UACR is a simple, accessible biomarker that can improve cardiorenal risk stratification.
💡 Clinical takeaway: Don’t wait for eGFR to decline. Measure UACR to identify patients at increased cardiovascular and HF risk—and act early.
#HeartFailure #Cardiorenal #Albuminuria #CKD #Cardiology #Nephrology #UACR #CardiovascularPrevention
@JavedButler1@mvaduganathan@gcfmd@SJGreene_md@GianluSava@HFA_President@hfcollaboratory
https://t.co/dfdjKqhXUo
🫀 Of 243,510 patients with newly diagnosed HF:
only 15.4% started an sMRA 😳
📉 HFrEF 29.6% | HFmrEF 14.0% | HFpEF 9.5%
🩺 Lowest uptake: HFpEF, yet <1 in 3 in HFrEF
⏱️ Median 10 days to start
🔗 https://t.co/fvZlMG0RH8
@HFSA#HFSA2026
Disease modification outcomes in type 2 diabetes: a modified Delphi.
https://t.co/D4QVg4pyZV
Contributions from Baim faculty, @JavedButler1 and Dr. Leigh Perreault.
#BaimInstitute#ClinicalResearch#T2D
Out now in @JACCJournals from #HFC members @tremartyn@JavedButler1@BiykemB et al.
This study analyzes trends in mortality, readmission, and home time after HF hospitalization from 2016–2022, including differences by race and Medicare plan type.
https://t.co/q87zvXGWOc